The FDA has approved drug label changes to six menopausal hormone replacement therapies (HRT), according to a recent news release. This was done to clarify risks for taking these drugs, specifically ...

The new labeling for the products does not include risk statements related to cardiovascular disease, breast cancer and probable dementia, the agency said.

Feb 12 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved labeling changes to six menopause ...

The FDA approved changes to the labels for six menopausal hormone therapy products in a move the agency said clarifies risk ...

The move to ease the restrictions was backed by The Menopause Society (TMS), which said the boxed warning "may have been a deterrent to the use of the low-dose vaginal estrogen, which is a safe and ...

HRT can also be a concern after treatment. If you’ve been treated for HR+ breast cancer, “There is always some small risk ...

The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for ...

A new study found that a combination of hormone therapy and the GLP-1 medication tirzepatide (Zepbound) led to 35% more ...

Hormone therapies for menopause will no longer carry a black box warning about serious risks such as breast cancer, heart attack and stroke, the Food and Drug Administration announced Monday. In the ...

BoomRx, the fastest-growing national pharmaceutical technology platform that simplifies prescription sourcing and fulfillment, today announced the availability of an oral liquid testosterone ...

Menopausal hormone replacement therapy (MHT) was once routinely used to relieve symptoms of menopause and protect against osteoporosis, heart disease, and possibly Alzheimer’s disease.

As we age, natural hormone levels decline and can fall out of balance, affecting both men and women with symptoms like low ...